Patents Assigned to ZymoGenetics, Inc.
  • METHOD OF TREATING HEPATOCELLULAR CARCINOMA
    Publication number: 20110052588
    Abstract: Materials and methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides.
    Type: Application
    Filed: March 23, 2010
    Publication date: March 3, 2011
    Applicant: Zymogenetics, Inc.
    Inventor: Thomas E. Palmer
  • Method of forming a peptide-receptor complex with zsig33
    Patent number: 7888056
    Abstract: The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: February 15, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Darrell C. Conklin
  • Anti-human IL-21 monoclonal antibodies
    Patent number: 7883700
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: February 8, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS
    Publication number: 20110014656
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Application
    Filed: June 30, 2010
    Publication date: January 20, 2011
    Applicant: ZYMOGENETICS, INC.
    Inventors: STEVEN D. LEVIN, MARK W. RIXON, GAO ZEREN
  • Methods of treating skin disorders using an IL-31RA antagonist
    Patent number: 7871618
    Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: January 18, 2011
    Assignee: ZymoGenetics, Inc.
    Inventor: Janine Bilsborough
  • Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
    Patent number: 7871616
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: January 18, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
  • Method of inhibiting the proliferation of B cell cancers using TACI-immunoglobulin fusion proteins
    Patent number: 7862814
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 4, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Anti-zB7H6 antibody-drug conjugates
    Patent number: 7858759
    Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: December 28, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao
  • FGF18 production in prokaryotic hosts
    Patent number: 7858341
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of FGF18 are described. The vectors utilize the FGF18 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the FGF18 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains, as well as OmpT and fhuA negative strains transformed with an FGF18 expression vector.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: December 28, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian J. Reardon, Susan H. Julien, Chung-leung Chan, Hong Y. Liu
  • Method for treating inflammation
    Patent number: 7855269
    Abstract: A method for treating down-regulating IL-19 or mda7 by administering the soluble IL-20RA/IL-20R heterodimeric receptor.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: December 21, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Stephen R. Jaspers
  • Human cytokine receptor
    Patent number: 7851594
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: December 14, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
    Patent number: 7842292
    Abstract: The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: November 30, 2010
    Assignees: Ares Trading S.A., Zymogenetics, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Herve Broly, Arnaud Ythier, Eric Sievers, Sharon J. Busby, Jan Öhrström, Ivan Nestorov, Stephen M. Ansell
  • IL-17A and IL-17F antagonists
    Patent number: 7842665
    Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: November 30, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Zeren Gao
  • USE OF HUMAN CYTOKINE RECEPTOR
    Publication number: 20100292151
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.
    Type: Application
    Filed: November 17, 2009
    Publication date: November 18, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • METHOD OF TREATING FIBRPROLIFERATIVE DISORDERS
    Publication number: 20100291087
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 18, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • PHARMACEUTICAL COMPOSITION COMPRISING FGF18 AND IL-1 ANTAGONIST AND METHOD OF USE
    Publication number: 20100291212
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 18, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
    Patent number: 7833529
    Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: November 16, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Jane A. Gross
  • Method for expanding hematopoietic cells using cytokine zalpha11 ligand
    Patent number: 7829075
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: November 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Antibody to mammalian cytokine-like polypeptide-10
    Patent number: 7829089
    Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: November 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
  • METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS
    Publication number: 20100266600
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 21, 2010
    Applicants: ZymoGenetics, Inc., National Jewish Medical Research Center
    Inventors: Donald Y.M. Leung, Janine Bilsborough, Jane A. Gross